The STAR STI CTG is a National Institutes of Health-sponsored clinical trials group that supports large, randomized clinical trials in the field of prevention, diagnosis, and treatment of STIs. The STAR STI CTG comprises 46 U.S. and international clinical research sites that include STD and sexual health clinics based in community settings and in health departments. These sites provide outstanding and unprecedented access to large and diverse populations of potentially eligible study participants.

Nearly 1.3 million patients were seen annually in key populations in major U.S. urban areas and international sites with strong clinical research infrastructure. Of these patients, 56 percent were female, and more than 4,000 were transgender. A major strength of the STAR STI CTG is diversity of its minority population worldwide.

The STAR STI CTG is tasked with developing and soliciting concept proposals in the areas of:

  • Antibiotic Resistance in STIs
  • Prevention of Preterm Birth and Stillbirth
  • Diagnostics of STIs
  • Neglected and Reemerging Diseases
  • Adolescent Health and Vaccines
  • Syphilis in Men who Have Sex with Men (MSM)
  • Drug-Resistant Gonorrhea (GC)
  • Pelvic Inflammatory Disease (PID)
  • Bacterial Vaginosis (BV)
  • Herpes and Chlamydia Vaccines

The funding for the STAR STI CTG is through an indefinite delivery indefinite quantity (IDIQ) contract awarded annually by the Division of Microbiology and Infectious Diseases.